Vincerx Pharma Stock Set to Reverse Split on Tuesday, January 28th (NASDAQ:VINC)

Vincerx Pharma, Inc. (NASDAQ:VINC) shares are scheduled to reverse split on the morning of Tuesday, January 28th. The 1-20 reverse split was announced on Thursday, January 23rd. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, January 27th.

Vincerx Pharma Trading Down 19.4 %

Shares of VINC stock traded down $0.03 during trading hours on Friday, reaching $0.10. 7,380,350 shares of the company’s stock were exchanged, compared to its average volume of 4,778,677. The stock has a market cap of $3.50 million, a PE ratio of -0.10 and a beta of 1.48. The stock’s fifty day moving average price is $0.22 and its two-hundred day moving average price is $0.46. Vincerx Pharma has a 1 year low of $0.10 and a 1 year high of $9.37.

Analysts Set New Price Targets

Separately, Leerink Partners cut their price target on shares of Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th.

Institutional Trading of Vincerx Pharma

An institutional investor recently bought a new position in Vincerx Pharma stock. Armistice Capital LLC bought a new position in shares of Vincerx Pharma, Inc. (NASDAQ:VINC) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,988,000 shares of the company’s stock, valued at approximately $1,610,000. Armistice Capital LLC owned 6.70% of Vincerx Pharma as of its most recent SEC filing. 44.02% of the stock is owned by hedge funds and other institutional investors.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.